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Received February 16, 2015; accepted May 30, 2015AbstractBackground: Magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT)
show promise for molecular cancer imaging. We evaluated 3T MRI, FDG PET/CT, and ultrasound images for asymptomatic women with an
abnormal screening mammogram.
Methods: The Institutional Review Board of Kaohsiung Veterans General Hospital (Kaohsiung, Taiwan) approved the study. Patients provided
written informed consent. A total of 11,865 screening mammograms of 118,65 women were performed at our facility between January 2011 and
December 2012. Fifty-three asymptomatic women (mean age, 53.3 years) whose screening mammograms had a Breast Imaging Reporting and
Data System (BI-RADS) category of 4 or 5 were ultimately enrolled in this study. Breast 3T MRI, FDG PET/CT, and breast ultrasound were
performed before biopsy. All imaging modalities were compared by lesion-by-lesion analyses.
Results: Fifty-nine breast lesions (28 malignant and 31 benign lesions) from 53 women were analyzed. The sensitivity, specificity, and accuracy
for 28 breast cancers were 96%, 77%, and 86%, respectively, for breast 3T MRI; 50%, 100%, and 76%, respectively, for FDG PET,CT; and 61%,
87%, and 74%, respectively, for breast ultrasound. One 0.8-cm invasive breast cancer was missed by the screening mammogram, but detected by
breast 3T MRI and FDG PET/CT. The sensitivity for detecting breast cancer was significantly higher with MRI than with PET/CT or ultrasound
(for all, p < 0.01). The specificity for detecting breast cancer was significantly higher for PET/CT than for breast MRI ( p ¼ 0.02). The sensitivity
exhibited by 3T breast MRI and FDG PET/CT for 16 noninvasive breast cancers was 94% and 25%, respectively.
Conclusion: On screening mammograms, breast 3T MRI showed higher sensitivity but less specificity than FDG PET/CT for detecting
asymptomatic breast cancers.
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Physicians have used conventional breast imaging tests such as
mammograms andbreast ultrasound for diagnosing patientswith a
lump in the breast. Early breast cancers are usually not palpable
and show only subtle findings on a mammogram.1e3 Mammo-
grams are widely used for breast cancer screening, but over-
diagnosis and underdiagnosis can occur in screening tests.1e3
Women assessed by the Breast Imaging Reporting and Data
System (BI-RADS) as category 4or 5on a screeningmammogram
are usually recommended for a definitive diagnosis with a biopsy.
Approximately 10 women per 1000 screened women require
further breast biopsy because of the suspicion of breast cancer.4
The biopsy recommendation rates, the breast cancer detection
rates, and the ratio of malignant to benign biopsies are correlated
with a radiologist's experience in interpreting screening mammo-
grams.5 The average percentage of biopsy-proven breast cancers
among screened women with a BI-RADS category of 4 or 5 was
reportedly 34%.6 A recent study has shown an increasing trend in
the biopsy rate and a decrease in the percentage of malignant bi-
opsy results for women receiving screening mammogram.5
A false-positive screening mammogram is associated with a
heightened breast cancer concern, uncertainty regarding the ben-
efits of screening, and a belief that abnormal test results do not
indicate that women have cancer.7 Additional or alternative im-
aging tests after an abnormal screening mammogram are of
particular importance to screened women, breast surgeons, and
breast radiologists.Womenwhohesitate tohaveabiopsymayseek
second opinions from other breast specialists or undergo alterna-
tive breast imaging tests such as breast magnetic resonance im-
aging (MRI), fluorodeoxyglucose (FDG) positron emission
tomography/computed tomography (PET/CT), and breast ultra-
sound. Positron emission tomography or FDG PET/CT has an
important role inbreast cancer staging, and is used topredictbreast
cancer recurrence and to restage breast cancer after therapy.8 An
MRIscanwith adedicatedbreast surface coil is verysensitive in its
capacity to detect clinically and mammographically occult breast
cancer in the contralateral breast in women with recently diag-
nosed breast cancer.9 Magnetic resonance imaging is the most
effective tool for screening breast disease in women at high risk.10
Recent research has found that 3T MRI yields a higher breast
cancer detection rate and positive predictive value than 1.5TMRI
for screeningwomen.11However,MRImayalsomiss certain early
calcified cancers that are commonly visible on a mammogram,
and it has ahigher false-positive rate.12ThenewlydevelopedPET/
MRI fusion imaging modality is another investigative tool that
could provide even further enhanced diagnostic capability in the
future.We investigated the clinical applications of breast 3TMRI,
FDGPET/CT, andbreast ultrasoundforpredictingbreast cancer in
women with abnormal mammograms.
2. Methods2.1. ParticipantsThis prospective study was compliant with the Health In-
surance Portability and Accountability Act (HIPAA) andapproved by the Institutional ReviewBoard (IRB) of Kaohsiung
Veterans General Hospital in Kaohsiung, Taiwan (IRB number
VGHKS11-CT4-13). All research participants provided written
informed consent. A total of 11,865 screening mammograms
from 11,865 women were obtained at our facility between
January 2011 and December 2012. Among these women, 1209
(10.2%) women had screen-positive results and were in BI-
RADS category 4 or 5.13 They were thereafter invited to
participate in this study. Fifty-fivewomen finished the complete
imaging tests. However, two women who ultimately refused to
undergo biopsy were excluded. The remaining 53 women
(mean age, 53.3 years; age range, 40e64 years) underwent
breast 3T MRI, FDG PET/CT, and breast ultrasound before
biopsy (Figs. 1 and 2). Their final histopathology findings were
compared with the results of all imaging tests.2.2. Full field digital mammogramAsymptomatic women who had a final BI-RADS category
of 4 or 5 on the mammogram were recommended to undergo
biopsies for positive screening results. These women each had
standard full field digital mammogram (Selenia Model;
Hologic Inc., Bedford, MA, USA), which consisted of the
mediolateral oblique (MLO) view and the craniocaudal (CC)
view. Furthermore, other diagnostic mammograms with addi-
tional views were performed for these equivocal mammo-
graphic findings.2.3. 3T MRIWith the patient prone, all MRI images were acquired with
a 3T scanner (Skyra; Siemens, Erlangen, Germany) that used a
16-channel bilateral breast coil. After axial localizer scanning,
morphological studies and dynamic studies were performed.
The dynamic study was performed using T1-weighted fast
low angle shot (FLASH) three-dimensional (3D) MRI with
fat-suppressed sequence and the following parameters: repe-
tition time/echo time (TR/TE), 4.7 /1.7 ms; flip angle, 10;
iPAT acceleration factor with GRAPPA, 2; matrix, 384  384;
field of view, 320 mm  320 mm; slice thickness, 1 mm; and
voxel size, 0.8 mm  0.8 mm  1 mm. The temporal acqui-
sition (range, < 60 seconds) was performed according to the
volume of the breasts and the field of view. Dynamic contrast-
enhanced MRI was started simultaneously with the injection
of 1.0M gadobutrol (Gadovist; Schering AG, Berlin-Wedding,
Germany) at a dose of 0.1 mmol/kg body weight by a power
injector at a rate of 2e3 mL/s and followed by a 10-mL saline
flush. The 3D sequence was acquired before the injection and
six times continuously after the injection of the contrast agent.
The acquired images were analyzed at a workstation (Syngo;
Siemens) for post processing with commercial software
(Syngo).2.4. FDG PET/CT imagingWomen who participated in this study fasted for at least 6
hours before undergoing FDG PET/CT imaging. Their serum
Fig. 1. Left breast invasive ductal carcinoma in a 50-year-old woman. (A) Screening mammogram mediolateral oblique (MLO) and craniocaudal (CC) views of the
left breast show an oval nodule (arrows) in the upper outer quadrant of the left breast. This lesion is classified as BI-RADS category 4a on the mammogram. (B)
The breast ultrasound shows a lobulated hypoechoic nodule in the left breast (arrow). This lesion is classified as BI-RADS category 4a on ultrasound. (C) The axial
fused FDG PET/CT image shows a nodule (arrows) and increased FDG uptake (the SUVmax is 3.6) in the left breast upper outer region. (D) Transverse dynamic
contrast-enhanced T1 FLASH 3D MRI using subtracted maximum intensity projection image and a 3T breast MRI shows a markedly enhanced mass (arrow) with
an irregular margin in the outer region of the left breast. This lesion was classified as BI-RADS category 4b on MRI. 3D ¼ three-dimensional; BI-RADS, Breast
Imaging Reporting and Data System; FDG PET/CT ¼ fluorodeoxyglucose positron emission tomography/computer tomography; FLASH ¼ fast low angle shot;
MRI ¼ magnetic resonance imaging; SUVmax ¼ maximum standardized uptake value.
Fig. 2. Right breast ductal carcinoma in situ in a 54-year-old woman. (A) The screening mammogram craniocaudal (CC) view and close-up view of the right breast
show segmental pleomorphic calcifications (arrow) in the right upper outer quadrant. This lesion was classified as a BI-RADS category 4b lesion on the
mammogram. (B) The axial fused PET/CT image shows no abnormal FDG uptake in the right breast outer region. (C) Transverse contrast-enhanced T1 FLASH 3D
MRI using a subtracted maximum intensity projection image, and the 3T breast MRI shows a nonmass segmental enhanced lesion (arrow) in the right breast outer
region. This lesion was classified as BI-RADS category 4c on breast MRI. The breast ultrasound shows no apparent lesion in the right breast in the corresponding
region (images not shown). 3D ¼ three-dimensional; BI-RADS¼Breast Imaging Reporting and Data System; FDG PET/CT ¼ fluorodeoxyglucose positron
emission tomography/computer tomography; FLASH ¼ fast low angle shot; MRI ¼ magnetic resonance imaging; SUVmax ¼ maximum standardized uptake value.
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FDG radioactive tracer. All women had blood glucose levels <
150 mg/dL at the time of the tracer injection. Each woman
received 370e555 MBq (10e15 mCi) of 18F-FDG, based on
her body weight (0.19 mCi/kg). After injecting the radioactive
tracer, the woman rested for ~60 minutes. Whole body FDG
PET/CT (Discovery ST-16; GE Healthcare, Milwaukee, WI)
was performed from the head to the upper thigh with the
woman supine.
Before PET scanning, CT scanning was performed with the
following parameters: 0.6 seconds per rotation, 120 kV,
100 mA, and 3.75-mm thick slices. After completing a plain
CT, PET images of the same areas were acquired in the two-
dimensional mode for 4 minutes per bed position.
Attenuation-corrected PET images were reconstructed using
an ordered subset expectation maximization iterative recon-
structed algorithm. The FDG PET/CT images were recon-
structed by the Xeleris functional imaging workstation (GE
Healthcare). A standardized uptake value (SUV) was deter-
mined semi-automatically on the Xeleris workstation.2.5. Breast ultrasoundBefore a woman underwent a biopsy, a breast ultrasound
was performed by one of four ultrasound technologists who
had 3e15 years of experience. The ultrasound technologists
performed the procedure using high-resolution (12-MHz
linear-array transducer) and ultrasound equipment Logiq-9
(GE Healthcare).2.6. Imaging interpretation
Table 1















1 1 (8) 0 (0) 2 (6) 3 (5)
4a 3 (25) 5 (31) 21 (68) 29 (49)All mammograms, MRIs, and ultrasounds were prospec-
tively evaluated by one of six scheduled breast radiologists
who had 3e20 years of experience. The radiology reports and
breast density were classified according to the BI-RADS cat-
egories.13,14 In addition, the PET/CT results were interpreted
by one of two qualified nuclear medicine physicians.4b 3 (25) 7 (44) 8 (26) 18 (30)
4c 4 (34) 4 (25) 0 (0) 8 (14)2.7. Pathohistology study
5 1 (8) 0 (0) 0 (0) 1 (2)
Breast MRI
1, 2, & 3 0 (0) 1 (6) 24 (77) 25 (42)
4a 1 (8) 7 (44) 4 (13) 12 (20)
4b 1 (8) 2 (13) 3 (10) 6 (10)
4c 6 (50) 5 (31) 0 (0) 11 (19)
5 4 (33) 1 (6) 0 (0) 5 (8)
Ultrasound
1, 2, & 3 3 (25) 8 (50) 27 (87) 38 (64)
4a 3 (25) 2 (13) 3 (10) 8 (14)
4b 1 (8) 2 (13) 0 (0) 3 (5)
4c 5 (42) 2 (13) 1 (3) 8 (14)
5 0 (0) 2 (13) 0 (0) 2 (3)
FDG PET/CTStereotactic biopsy was performed utilizing a handheld 10-
gauge vacuum-assisted biopsy system (Vacora System; Bard
Biopsy Systems, Tempe, AZ, USA). Ultrasound-guided biopsy
was performed by a freehand technique with a Magnum 14G
automatic biopsy gun (Bard Biopsy Systems). All participants
with biopsy-proven breast malignancy underwent a definitive
surgical treatment in compliance with the standard institu-
tional protocol. The pathologic tumor stages after therapeutic
surgery were determined according to the recently revised
seventh edition of the American Joint Committee on Cancer
(AJCC) Cancer Staging Manual.15Non-FDG-avid 2 (17) 12 (75) 31 (100) 45 (76)
FDG-avid 10 (83) 4 (25) 0 (0) 14 (24)
2.8. Statistical analysisData are presented as n (%).
BI-RAD¼Breast Imaging Reporting and Data System; FDG PET/
CT ¼ fluorodeoxyglucose positron emission tomography/computed tomogra-
phy; MRI ¼ magnetic resonance imaging.Sensitivity, specificity, and the positive and negative pre-
dictive values were employed to describe the diagnostic valueof breast MRI, PET-CT, and breast ultrasound in evaluating
mammographically detected questionable lesions. The detec-
ted lesions on breast 3T MRI, breast ultrasound, and FDGPET/
CT were calculated for statistical analysis. McNemar's test for
correlated proportions was utilized to assess the significance
for sensitivity, specificity, and accuracy. Statistical calculations
were performed using SPSS software (SPSS for Windows,
version 19; SPSS Inc., Chicago, IL, USA). Findings with
p < 0.05 were considered statistically significant.
3. Results
The 53 screened women were classified in BI-RADS
category 4a [28 (53%) women], category 4b [15 (28%)
women], category 4c [(17%) women], and category 5 [1 (2%)
women]. Breast density categories were heterogeneously
dense (n ¼ 32) and extremely dense (n ¼ 21). The histology
results were benign breast disease (31 women), ductal carci-
noma in situ (DCIS; 16 women), invasive lobular carcinoma (1
woman), and invasive ductal carcinoma (IDC; 11 women;
Table 1). The maximal tumor size of the invasive breast cancer
ranged 0.1e3.3 cm (mean, 1.2 cm). One woman had both IDC
(0.8 cm) and DCIS in her ipsilateral breast; the IDC was
missed by the screening mammogram but detected by breast
3T MRI and by FDG PET/CT.
The major mammographic finding of 59 lesions was
calcification [42 (71%) women]. Among 16 noninvasive breast
cancers, the tumors presented with calcification (n ¼ 14), as a
mass (n ¼ 1), or with architectural distortion (n ¼ 1). Among
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cation (n ¼ 6), as a mass (n ¼ 2), focal asymmetry (n ¼ 3), or
with negative findings (n ¼ 1). Approximately 71% (22/31) of
benign lesions also presented with calcifications.
Breast 3T MRI depicted 12 (100%) of 12 invasive breast
cancers and 15 (94%) of 16 noninvasive breast cancers. The
MRI scan missed one DCIS that appeared as a cluster of
microcalcifications on screening mammogram. The mean size
of invasive breast cancers on breast MRI was 1.9 cm (range,
0.8e3.7 cm). Breast ultrasound depicted nine (75%) of 12
invasive breast cancers and eight (50%) of 16 noninvasive
breast cancers. The mean size of an invasive breast cancer on
ultrasound was 1.8 cm (range, 0.6e3.3 cm).
Among 59 breast lesions, 14 lesions were FDG-avid and 45
lesions were nonFDG-avid. The FDG PET/CT scans, which
were performed with the women supine, depicted 10 (83%) of
12 invasive breast cancers and four (25%) of 16 noninvasive
breast cancers. The SUV in breast cancers ranged from un-
detectable levels to 8.6. The maximum SUV (SUVmax) of 14
PET/CT-detected breast cancers ranged 1.7e8.6 (mean value,
3.1 ± 1.8). No benign lesion showed a positive finding on
PET/CT. Breast cancers that were missed by FDG PET/CT
imaging were small invasive breast cancer (size, < 0.5 cm) or
noninvasive breast cancers. The mean size of invasive breast
cancer on FDG PET/CT was 1.3 cm (range, 0.8e2.7 cm).
The sensitivity, specificity, and accuracy of the imaging
tools in analyzing 59 breast lesions were measured and
compared (Table 2). The sensitivity of breast MRI in detecting
breast cancers was significantly higher than the sensitivity of
FDG PET/CT ( p < 0.01) and breast ultrasound ( p < 0.01).
The specificity of FDG PET/CT for breast cancer diagnosis
was significantly higher than the specificity of breast MRI
( p ¼ 0.02). The accuracy in differentiating benign lesions
from malignant breast lesions was significantly higher in
breast 3T MRI than in FDG PET/CT ( p < 0.01) or breast
ultrasound ( p < 0.01). There were no significant differences in
communication between FDG PET/CT and breast ultrasound.
Breast MRI had significantly higher diagnostic accuracy than
FDG PET/CT and ultrasound (for all, p < 0.01).
Among 12 patients with invasive breast malignancies, 11
patients had subsequent surgery for the breast tumor and oneTable 2
Quantitative analysis of breast 3T MRI, ultrasound, PET/CT for diagnosing 59
lesions.
Imaging test Sensitivity a Specificity b Accuracy c PPV NPV
Breast 3T MRI 96 77 86 79 96
FDG PET/CT 50 100 76 100 69
Ultrasound 61 87 74 81 71
Data are presented as %.
FDG PET/CT ¼ fluorodeoxyglucose positron emission tomography/computed
tomography; MRI ¼ magnetic resonance imaging; NPV ¼ negative predictive
value; PPV ¼ positive predictive value.
a Sensitivity: MRI versus PET/CT, p < 0.01; MRI versus ultrasound,
p < 0.01.
b Specificity: MRI versus PET/CT, p ¼ 0.02.
c Accuracy: MRI versus PET/CT, p < 0.01; MRI versus ultrasound,
p < 0.01.patient refused any treatment. Only one patient had axillary
lymph node metastases on surgery. The T (i.e., tumor size)
stage according to the pathological staging (pTNM) was 1a
(n ¼ 3), 1b (n ¼ 3), 1c (n ¼ 4), and T2 (n ¼ 1), based on the
seventh edition of the AJCC Cancer Staging Manual.
Table 3 shows the preoperative estimation of the tumor size
by different imaging modalities. A higher T stage was incor-
rectly assigned by breast 3T MRI for six (55%) invasive breast
cancers, by FDG PET/CT for three (28%) invasive breast
cancers, by ultrasound for two (17%) invasive breast cancers,
and by mammogram for four (36%) invasive breast cancers.
An underestimated T stage was assigned by FDG PET/CT in
17% of patients, by ultrasound in 28% of patients, by
mammogram in 28% of patients, and by MRI in 0% of
patients.
4. Discussion
Amammogram has limitations in its capacity to detect breast
cancer in dense and heterogeneously dense breasts.16 In fact,
mammograms with a BI-RAD category of 4 or 5 are clinical
puzzles because of the wide range of malignancy possibilities
(2e95%).17 The positive predictive values for a biopsy of
calcification detected by a screening mammogram are generally
low because of the greater diagnostic uncertainty.17 Breast MRI
and FDG PET/CT are also commonly used for diagnosis and
staging breast cancer. We found that breast 3TMRI had a higher
sensitivity and accuracy than FDG PET/CT and breast ultra-
sound. We also presented the pros and cons of PET/CT and 3T
breast MRI separately. Combining mammography, ultrasound,
and MRI provide increased sensitivity and reliability, compared
to using an individual imaging test alone.16 This study indicated
that, because of their unique diagnosticmethodologies, breast 3T
MRI and PET/CT could be helpful for evaluating asymptomatic
women with an abnormal mammogram. Future PET/MR hybrid
systems may provide additional clinical applications for breast
cancer patients.
A previous investigation reported that 48% of DCIS could
be missed by mammogram but diagnosed by MRI alone.18 We
have noted a scarcity of lesion-based studies using mammo-
grams, breast ultrasound, FDG PET/CT, and breast 3T MRI
for breast lesions. The advantages of using high-cost FDG
PET/CT or PET/MRI for more effective assessment of
potentially troubling breast lesions remain unclear. We found
that FDG PET/CT could find 50% of screening-detected breastTable 3
Difference in the preoperative size of 11 tumors estimated by each modality,
based on tumor size (T) in TNM staging.
Imaging test Overestimate Accurate Underestimate
Mammogram 4 (36) 4 (36) 3 (28)
Breast 3T MRI 6 (55) 5 (45) 0 (0)
FDG PET/CT 3 (27) 6 (55) 2 (18)
Ultrasound 2 (17) 6 (55) 3 (28)
Data are presented as n (%).
FDG PET/CT ¼ fluorodeoxyglucose positron emission tomography/computed
tomography; MRI ¼ magnetic resonance imaging.
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invasive. However, FDG PET/CT revealed no false-positive
results for screening-positive women.
We demonstrated that MRI could diagnose 94% of nonin-
vasive breast cancers and 100% of invasive breast cancers.
Breast MRI has also shown high negative predictive values for
questionable lesions.
The benefits of breast 3T MRI include increased signal-to-
noise ratio, higher temporal and spatial resolution, and shorter
MRI scanning time. The common disadvantages of breast MRI
are the high cost and high false-positive rates.19
Dynamic contrast-enhanced MRI is commonly employed
to explore the angiogenesis and vessel permeability of ques-
tionable lesions in the breast.20 Except for lesions in which a
malignancy was highly suspected on the mammogram, breast
lesions that show no enhanced areas may be safely followed in
view of the minute possibility of breast cancer.21 A breast
screening study18 showed 1.5T MRI had good results for DCIS
with a high nuclear grade. The diagnostic pitfall of MRI could
occur as the result of nonenhancing early breast cancerdin
particular, low-grade DCIS could be missed.18 A negative
MRI also indicated a relatively low risk for BI-RADS category
4 or 5 mammographic lesions.18
Fluorodeoxyglucose PET/CT can be an effective tool in
detecting distant metastases in patients with breast cancer.22
However, the utility of FDG PET/CT in assessing a primary
breast tumor is somewhat uncertain. Furthermore, the problemof
radiation exposure and the higher expense of FDG PET versus
other modalities continue to be noteworthy. Only small-scale
studies with limited numbers of study participants have been
conducted to compare the performance and efficacy between
FDG PET/CT, mammogram, breast ultrasound, and breast MRI.
Motion in the chest wall during patient respiration in the supine
position can cause breathing artifacts during FDG PET/CT
scanning. Previous research using FDG PET reported a lower
detection rate of small breast cancer (size, < 1 cm).23 In this
study, the size of invasive breast cancer ranged 0.1e3.3 cm. The
FDGPET/CT test wasmore sensitive in detecting invasive breast
cancers (10/12, 83.3%) than in detecting noninvasive breast
cancers (4/16, 25%). Approximately 58% (7/12) of invasive
cancers in this study were < 1 cm, which demonstrated that
FDGPET/CT can also detect small invasive breast cancers.
Furthermore, FDG PET/CT showed different diagnostic results
between invasive and noninvasive breast cancer because nonin-
vasive breast cancers often presented as noneFDG-avid.
Ultrasound imaging showed a higher sensitivity for invasive
breast cancer (9/12, 75%) than for noninvasive breast cancer (8/
16, 50%). Our study demonstrated a relatively low detection rate
of breast ultrasound. Invasive breast cancers presenting with
architectural distortion or calcifications were difficult to identify
by ultrasound. Breast ultrasound in this study was administered
by ultrasonographers. This is of some consequence because a
previous study showed a lower procedural accuracy in the groups
whose ultrasounds were performed by sonographers alone,
compared to ultrasonographers and radiologists.24
One study shows that the IDC size could be underestimated
by ultrasound, but there is no similar estimation issue withmammogram, and MRI seems to overestimate the IDC size in
comparison to the pathology results.25 In our MRI study,
~55% of IDCs were overestimated but none of them was
underestimated. We suspect the overestimation by MRI may
be related to contrast enhancement that occurs with the com-
binations of invasive cancers, noninvasive breast cancers, and
adjacent tumor-induced desmoplastic reaction.
The limitations of this study include the relatively small
sample size in the preliminary lesion-by-lesion multimodality
comparisons. Because of the high cost and radiation exposure
to patients, we could not establish a large-scale lesion-based
prospective study that incorporated both PET/CT and MRI. We
selected women with BI-RADS category 4 or 5 mammographic
lesions as our “target women” because this category of patient
has a higher-than-average probability of malignancy. There is a
need for additional PET/MRI imaging studies to investigate the
clinical application of PET and MRI.26
From our preliminary study, we demonstrated the advan-
tages and disadvantages of combined imaging information
from PET and MRI for diagnosing breast cancers. Our pre-
liminary results showed that breast 3T MRI has higher
sensitivity and PET/CT has higher specificity for predicting
breast cancer in asymptomatic women with an abnormal
mammogram.
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